Navigation Links
International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCool's New Investigational UroCool System
Date:1/14/2009

theter to allow for localized cooling. Drs. Ahlering and Finley believe that therapeutic cooling of the prostate gland and surrounding areas during prostate surgery (which includes both traditional open surgical approaches and the newer robotic-assisted technique) offers the potential to reduce tissue damage and inflammation and thereby provide a faster return of bladder control (continence) and possibly erectile function (potency) following surgery.

"We are pleased that Dr. Ahlering, one of the nation's experts in the field of robotic-assisted prostate surgery, had the opportunity to present his findings of the benefits of cooling during robotic-assisted prostatectomy and to introduce InnerCool's new investigational UroCool(TM) catheter system to other experts in his field. In late 2008, we announced the licensing of UroCool related technology from the University of California, Irvine, patient enrollment in the Hypothermic Radical Prostatectomy study being conducted by Dr. Ahlering and his associates, and our plans to submit a regulatory application for FDA 510(k) clearance for the new UroCool(TM) catheter in first quarter 2009," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies.

Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancers. One in six men will develop prostate cancer in their lifetime, and in 2007 over 200,000 men were newly diagnosed with the disease. Fortunately, prostate cancer grows relatively slowly and 7 out of 10 men are diagnosed in the early stages of the disease before it has spread to other parts of their body, thus leading to significantly increased survival with proper treatment. While the underlying cause for the development of prostate cancer is still unknown, factors such as age, race, and lifestyle affect the probabi
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal
2. Palomar and Q-MED AB Terminate International Distribution Agreement
3. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
4. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
5. ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement
6. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
7. Probiotic Delivery Technology Awarded Third International Patent
8. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
9. The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy
10. Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and i.v.Station(TM PENDING) Robots
11. MINRAD International, Inc. Announces Reduction in Workforce
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Many factors impact tissues targeting ... efflux transporters at the blood-tissue barrier. Even when tissue ... fractions in the tissue rather than the total tissue ... is required to guide lead optimization, predict in vivo ... variables that may impact the likely human clinical dose. ...
(Date:5/23/2013)... Every day, their baby stopped breathing, his collapsed ... lungs. April and Bryan Gionfriddo watched helplessly, just praying ... a few doctors said he had a good chance ... about her now 20-month-old son, Kaiba. "At that point, ... take it and run with it." , They found ...
(Date:5/23/2013)... Patheon Inc ., a leading provider of ... industry, will host a complimentary webinar on “Cleaning Validation: ... June 4, 2013 at 11 a.m. Eastern Standard Time. ... with regulations for cleaning validation. Many companies have ... little evaluation of risk. Some companies have chosen ...
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
Breaking Biology Technology:DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... the Company,s workforce, resulting in a reduction in staff of ... due to the Complete Response Letter it received from the ... on January 31, 2011 regarding the New Drug Application (" ...
... ERES ) announced today that it will release its ... March 1, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
... HIGHLIGHTS:2010 Results (all percentages are to comparable periods in ... million, a new quarterly high. Q4 sales grew by 2% and ... 2010 sales increased 6% and 5% on a reported and currency ... EPS was $0.76. Excluding restructuring costs of $0.07, adjusted Q4 2010 ...
Cached Biology Technology:Orexigen® Therapeutics Announces Corporate Realignment 2Orexigen® Therapeutics Announces Corporate Realignment 3ERT Reports Fourth Quarter and Full Year 2010 Operating Results on March 1, 2011 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13
(Date:5/23/2013)... Laboratory honored more than 165 staff for their ... PNNL,s annual Intellectual Property Commercialization Recognition & Rewards ... national laboratory named materials scientist Jun Liu Inventor ... materials that can store large amounts of energy, ... the time it takes to charge cell phones, ...
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
(Date:5/23/2013)... cerebral palsy with autologous cord blood. Following a cardiac ... boy had been in a persistent vegetative state ... treatment with the cord blood containing stem cells, the ... learned to speak simple sentences and to move. "Our ... the long-held doubts about the effectiveness of the new ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Biochemistry: Unspooling DNA from nucleosomal disks 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... and diesel with plant-based bio fuels is crucial to curb climate ... and some of the methods result in bio fuels that are ... from the University of Copenhagen shows that it is possible to ... single drop. This promises cheaper, faster and above all safer development ...
... usually progresses in small steps, but on rare occasions, ... produces a ,great leap forward., An international team of ... Joseph Ecker, report one such leap in the July ... their mapping and early analyses of thousands of protein-to-protein ...
... 29, 2011Intravenous delivery of cold fluids to reduce body ... outcomes may not be as effective in children as ... in Therapeutic Hypothermia and Temperature Management , a ... article is available free online at www.liebertpub.com/ther ...
Cached Biology News:Computational chemistry shows the way to safer biofuels 2Scientists take a giant step for people -- with plants! 2Scientists take a giant step for people -- with plants! 3Scientists take a giant step for people -- with plants! 4